Biotech Values

[DewDiligence]

Misconstruing the Ipilimumab data…

From the DNDN board on iV:

http://investorvillage.com/smbd.asp?mb=971&mn=395213&pt=msg&mid=10295896

3/25/2011 4:34:09 PM by bull trout

…compared to Provenge, the results from this study seem very weak.

About 85 percent of patients had little response to the drug ....The FDA said severe to fatal immune reactions occurred in 12.9 percent of patients during clinical trials. These numbers add up to 97.9% of the patients treated... that means the drug helped up to 2.1% of patients without nearly killing them.

No, that’s not at all what these data mean! Not one poster on that message board corrected this nonsensical statement but nine readers of the board recommended it, which may say something about what kinds of investors are long DNDN.